Axsome Therapeutics CEO Herriot Tabuteau Exercises and Sells Stock Options

Axsome Therapeutics, Inc. CEO Herriot Tabuteau filed a Form 4 disclosing significant stock transactions on July 1, 2026. Tabuteau exercised 49,666 stock options at $4.95 per share and immediately sold the same number of shares at $240.25 per share, resulting in substantial proceeds. The transactions were executed under a pre-approved 10b5-1 trading plan and were necessary due to the options approaching their 10-year expiration date in March 2027. Following these transactions, Tabuteau directly holds 7,229 shares and indirectly controls 7,344,500 shares through an entity. The exercise price of the options was $240.25, and the sale price represented a weighted average across transactions ranging from $237.64 to $244.71 per share.